DEC 18, 2017 5:38 PM PST

Next Generation Antibody Therapeutics

WRITTEN BY: Courtney Schaal

Antibodies have been gaining traction in the clinical drug pipeline for the past three decades, and have shown great efficacy and promise in many diseases involving immune response including chronic inflammation, cancer, and autoimmune diseases to name a few. According to a recent article written by Paul Carter and Greg Lazar from the Department of Antibody Engineering at Genentech Incorporated, in San Francisco California, there have been over 60 antibody based drugs approved for therapeutic use and are currently marketed with world-wide revenues of approximately 89 billion dollars in the United States. This amount of revenue is enough to grab your attention, as well as others in the drug production industry. Carter and Lazar also note that there are over 550 antibodies currently in clinical development, which includes more than 50 in phase III clinical trials, which is incredibly promising.

This makes antibodies for treatment of disease one of the most rapidly growing drug classes currently being pursued, and they have so far proven to have great effect. Antibodies that essentially act by some mechanism or another to aid immune cells to recognize tumor cells to destroy them and eradicate them from the body is one example of successful employment of antibody drugs that has exploded in the last several years. These include antibodies specific to antigens such as CTLA4, CD20, CD22, EGFR, CCR4, HER2, IL-1alpha, PD1, PDL1, RANKL, and VEGF – again – just to name a few. These acronyms each represent molecules that play a role in various types of cancer progression that when target can diminish the cancer. This also has been found to be effective in multiple cancer types such as leukemias, lymphomas, melanomas, colorectal, head and neck, lung, breast, skeletal, and even brain cancers – which is highly impressive considering that each of these cancer types is a disease unto itself having different driver mutations and mutational burdens. They all have one thing in common that is exploitable by antibodies therapeutically, however, and that is they can evade the immune system. Antibodies enable the immune system to once again recognize the tumor, which results in subsequent tumor cell killing. Antibody drugs are also in use for diseases such as multiple sclerosis, Crohn’s disease, ulcerative colitis, lupus, psoriasis, asthma, arthritis, and others which all have the commonality of an immune system component implicated in some aspect of the disease. Antibodies are even being studied for use in prevention of migraines. This is a pretty impressive list of diseases for which antibodies may prove effective drug strategies.

Currently, the new and emerging antibodies are being expanded and according to the article by Carter and Lazar, “novel mechanisms of action of antibodies and innovative targeting strategies that could extend their therapeutic applications, including antibody-drug conjugates, bispecific antibodies, and antibody engineering to facilitate more effective delivery” are underway. “These strategies could enable the pursuit of difficult to hit, less well understood or previously undruggable targets – the ‘high-hanging fruit’. So not just antibodies targeting disease drivers themselves or eliciting immune reponse to disease, but also arming such antibodies with other drugs to deliver directly to indicated sites, and also creating antibodies with dual-specificities to hit two targets, or creating new specificities all together. This is an exciting time for the world of antibody drug discovery, and should prove to have great implications for patients in the clinic.

Sources: Nature Reviews Drug Discovery, Pixabay, Youtube, Roche

Roche's summary of antibodies in medicine:

 

About the Author
You May Also Like
APR 28, 2022
Drug Discovery & Development
Keto Molecule Shows Promise for Treating Colorectal Cancer
APR 28, 2022
Keto Molecule Shows Promise for Treating Colorectal Cancer
A molecule produced when on low-carbohydrate ketogenic diets suppresses the growth of colorectal tumors in the lab. The ...
JUN 02, 2022
Coronavirus
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
JUN 02, 2022
Loneliness and social isolation may continue to prolong the COVID-19 pandemic
It has been clear for some time that loneliness and social isolation can lead to increased risks for adverse h ...
JUN 06, 2022
Drug Discovery & Development
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
JUN 06, 2022
New Antibiotic Shows Promise Against Treatment-Resistant Tuberculosis
A new class of antibiotics has shown promise in preclinical trials against drug-resistant tuberculosis. The correspondin ...
JUN 24, 2022
Drug Discovery & Development
Pain Medications with High Abuse Potential More Likely to Achieve Approval
JUN 24, 2022
Pain Medications with High Abuse Potential More Likely to Achieve Approval
Researchers found that pain medications with a high potential for abuse are more likely to be approved than medications ...
JUN 26, 2022
Drug Discovery & Development
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
JUN 26, 2022
Vitamin Supplements are a 'Waste of Money' for Healthy Americans
The US Preventive Services Task Force (USPSTF) recommends against using beta carotene or vitamin E supplements to preven ...
JUL 01, 2022
Drug Discovery & Development
Paper-thin Device Treats Pain and then Dissolves in Body
JUL 01, 2022
Paper-thin Device Treats Pain and then Dissolves in Body
Researchers have developed a biocompatible, implantable device that relieves pain and harmlessly dissolves when no longe ...
Loading Comments...